Nanobiotix 2018 Annual Results

Paris, France and Cambridge, Massachusetts, USA, March 15, 2019 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited1 consolidated results

Read More

Nanobiotix 2018 Annual Results

Paris, France and Cambridge, Massachusetts, USA, March 15, 2019 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited1 consolidated results

Read More